Yu, Ming-Lung <br/><br/>
Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.  [electronic resource] 

 -  Journal of the Formosan Medical Association = Taiwan yi zhi  Jun 2018 
 - 518-526 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0929-6646 
<br/><br/><label>Standard No.: </label>10.1016/j.jfma.2017.06.006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Aged<br/>Alanine Transaminase--blood<br/>Anilides--adverse effects<br/>Antiviral Agents--adverse effects<br/>Carbamates--adverse effects<br/>Cyclopropanes<br/>Drug Therapy, Combination<br/>Female<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--complications<br/>Humans<br/>Lactams, Macrocyclic<br/>Liver Cirrhosis--physiopathology<br/>Liver Transplantation<br/>Macrocyclic Compounds--adverse effects<br/>Male<br/>Middle Aged<br/>Postoperative Period<br/>Proline--analogs & derivatives<br/>Ribavirin--adverse effects<br/>Ritonavir--adverse effects<br/>Sulfonamides--adverse effects<br/>Sustained Virologic Response<br/>Uracil--adverse effects<br/>Valine